To test if changes in global methylation influenced the clinical benefit of ICIs, Jung et al. studied the methylome and exome of tumor specimens from NSCLC patients treated with anti-PD-1/PD-L1. This evidence concerns the gene CD274 and non-small cell lung carcinoma.